(3-氨基苯基)(1-吡咯烷)甲酮 | 160647-74-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (3-氨基苯基)(1-吡咯烷)甲酮
• 英文名称: (3-aminophenyl)(pyrrolidin-1-yl)methanone
• 英文别名: (3-aminophenyl)-pyrrolidin-1-ylmethanone
• CAS: 160647-74-5
• 化学式: C₁₁H₁₄N₂O
• mdl: MFCD09045578
• 分子量: 190.245
• InChiKey: DKAPTTYZYHVSIO-UHFFFAOYSA-N

物化性质

• 沸点：
  394.4±25.0 °C(Predicted)
• 密度：
  1.195±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-[(Pyrrolidin-1-yl)carbonyl]aniline
Synonyms: 3-(pyrrolidin-1-ylcarbonyl)aniline

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-[(Pyrrolidin-1-yl)carbonyl]aniline
CAS number: 160647-74-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11 H14 N2 O
Molecular weight: 190.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (3-氨基苯基)(1-吡咯烷)甲酮 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 3-(吡咯啉-1-甲基)苯胺
  参考文献：
  名称：

  Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors

  摘要：

  式(I)的化合物： 其中Ra、Rb、R、X1和X2如所定义，提供了包括所述化合物的药物组合物、制备过程和使用方法。

  公开号：

  US20090082379A1
• 作为产物：
  描述：

  (3-nitrophenyl)(pyrrolidin-1-yl)methanone 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 生成 (3-氨基苯基)(1-吡咯烷)甲酮
  参考文献：
  名称：

  METHODS OF CONTROLLING CROP PESTS USING AROMATIC AMIDE INSECT REPELLENTS, METHODS OF MAKING AROMATIC AMIDE INSECT REPELLENTS, AND NOVEL AROMATIC AMIDE INSECT REPELLENTS

  摘要：

  本文公开了保护水果作物免受飞行昆虫害虫侵害和使用芳香酰胺化合物驱逐飞行昆虫的方法。该方法将化合物应用于各种表面，例如水果作物、地面或与水果作物相邻的结构、物品、文章、人体皮肤或动物。化合物的化学式为RxC6Hy—C（═O）—N（Cy），其中RxC6Hy是取代苯基，每个R基独立地为C1-C6烷基、取代的C1-C4烷基、（取代的）C6-C10芳基、C1-C4甲氧基、C6-C10芳氧基、卤素、硝基、氰基、氰酸酯、异氰酸酯、亚硝基、C1-C4烷基硫基、苯基硫基、（卤素取代的）C1-C4烷基磺酰基、苯基磺酰基、甲苯基磺酰基、氨基、单或双C1-C4烷基氨基、二苯基氨基、二C1-C4烷基酰胺基、甲酰基、C2-C7酰基或C1-C6烷氧羰基；x为1至5的整数；x+y=5；Cy为C2-C8（取代的）烷二基、C4-C6（取代的）烯二基或式为—（CH2CH2）—O—（CH2CH2）—、—（CH2CH2）—NR′—（CH2CH2）—或—（CH2CH2）—S—（CH2CH2）—的（取代的）二基，与酰胺N原子一起形成非芳香环；R′为C1-C6烷基、取代的C1-C4烷基、（取代的）C6-C10芳基或（取代的）苄基。

  公开号：

  US20220071213A1
• 作为试剂：
  描述：

  间氨基苯甲酸 、 2-(1h-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 四氢吡咯 在 氯化铵 、 水 、 乙酸乙酯 、 Brine 、 Sodium sulfate-III 、 crude product 、 silica gel 、 (3-氨基苯基)(1-吡咯烷)甲酮 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以to give (3-aminophenyl)(pyrrolidin-1-yl)methanone (compound 15A, 400 mg, 60%) as yellow solid的产率得到(3-氨基苯基)(1-吡咯烷)甲酮
  参考文献：
  名称：

  Benzazepine Dicarboxamide Compounds

  摘要：

  本发明涉及一种新型苯并氮杂二酰胺化合物，其化学式为其中R1至R4如所述和权利要求书中定义的，以及其药学上可接受的盐。这些化合物是TLR激动剂，因此可能作为治疗癌症、自身免疫疾病、炎症、败血症、过敏、哮喘、移植排斥、移植物抗宿主病、免疫缺陷和感染性疾病等疾病的药物有用。

  公开号：

  US20160257653A1

文献信息

• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2013096153A1

  公开（公告）日：2013-06-27

  The invention is directed to substituted quinoline derivatives. Specifically, the invention is directed to compounds according to Formula I: wherein R, R1, R2, R3 and R4 are defined herein. The compounds of the invention are inhibitors of lactate dehydrogenase A and can be useful in the treatment of cancer and diseases associated with tumor cell metabolism, such as cancer, and more specifically cancers of the breast, colon, prostate and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting lactate dehydrogenase A activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  本发明涉及取代喹啉衍生物。具体而言，本发明涉及根据公式I的化合物：其中R，R1，R2，R3和R4按如下定义。本发明的化合物是乳酸脱氢酶A的抑制剂，可用于治疗癌症和与肿瘤细胞代谢有关的疾病，例如癌症，更具体地说是乳腺癌、结肠癌、前列腺癌和肺癌。因此，本发明进一步涉及包含本发明化合物的药物组合物。本发明还进一步涉及使用本发明的化合物或包含本发明化合物的药物组合物来抑制乳酸脱氢酶A活性和治疗与之相关的疾病的方法。
• Synthesis and Characterization of a Bidirectional Photoswitchable Antagonist Toolbox for Real-Time GPCR Photopharmacology
  作者：Niels J. Hauwert、Tamara A. M. Mocking、Daniel Da Costa Pereira、Albert J. Kooistra、Lisa M. Wijnen、Gerda C. M. Vreeker、Eléonore W. E. Verweij、Albertus H. De Boer、Martine J. Smit、Chris De Graaf、Henry F. Vischer、Iwan J. P. de Esch、Maikel Wijtmans、Rob Leurs

  DOI：10.1021/jacs.7b11422

  日期：2018.3.28

  precision are in great demand. Photopharmacology uses photons to control in situ the biological properties of photoswitchable small-molecule ligands, which bodes well for chemical biological precision approaches. Integrating the light-switchable configurational properties of an azobenzene into the ligand core, we developed a bidirectional antagonist toolbox for an archetypical family A GPCR, the histamine

  非常需要以时间和空间精度调节 G 蛋白偶联受体 (GPCR) 的无创方法。光药理学使用光子来原位控制光可切换小分子配体的生物学特性，这预示着化学生物学精密方法的发展。将偶氮苯的光控构型特性整合到配体核心中，我们为原型 A GPCR 家族（组胺 H3 受体 (H3R)）开发了双向拮抗剂工具箱。从 16 种新合成的光可开关化合物中，选择了 VUF14738 (28) 和 VUF14862 (33)，因为它们在 360 nm 照射下迅速且可逆地发生光异构化，并且 H3R 结合亲和力分别增加或减少了 10 倍以上。两种配体都将长热半衰期与快速和高光化学反式/顺式转换相结合，允许它们用于卵母细胞的实时电生理学实验，以确认在重复的二级循环中 H3R 活化的动态光调制。VUF14738 和 VUF14862 是稳健且抗疲劳的光开关 GPCR 拮抗剂，适用于 H3R 信号传导的时空研究。
• [EN] PEPTIDES, COMPOUNDS, COMPOSITIONS AND METHODS FOR INHIBITING SOX9 DIMERIZATION<br/>[FR] PEPTIDES, COMPOSÉS, COMPOSITIONS ET PROCÉDÉS POUR INHIBER LA DIMÉRISATION DE SOX9
  申请人：BROWN ARTHUR

  公开号：WO2021097552A1

  公开（公告）日：2021-05-27

  The present application provides SOX9 dimerization inhibitor compounds, compositions, and methods of use thereof. In certain aspects, the SOX9 dimerization inhibitor is a peptide comprising a portion of the SOX9 dimerization motif and a TAT protein to support cell entry which is c-terminal to the SOX9 dimerization motif as set forth in SEQ ID NO:3. In other aspects, the SOX9 dimerization inhibitor is a compound of the general formula I (The applicant is kindly asked to please insert chemical structure here) where one A is H and the other is: (please insert second chemical structure here), and the remaining substituents are as defined in the application.

  本申请提供SOX9二聚体化抑制剂化合物、组合物及其使用方法。在某些方面，SOX9二聚体化抑制剂是一种肽，包括SOX9二聚体化基序的一部分和一个TAT蛋白，用于支持细胞进入，该TAT蛋白位于SOX9二聚体化基序的C端，如序列号为3的SEQ ID中所述。在其他方面，SOX9二聚体化抑制剂是一种符合一般式I的化合物（申请人请在此处插入化学结构），其中一个A为H，另一个为：（请在此处插入第二个化学结构），其余取代基如申请中所定义。
• [EN] AMINO-SUBSTITUTED ISOTHIAZOLES<br/>[FR] ISOTHIAZOLES AMINO-SUBSTITUÉS
  申请人：BAYER PHARMA AG

  公开号：WO2015113920A1

  公开（公告）日：2015-08-06

  The present invention relates to amino-substituted isothiazoles of general formula (I) : in which A, R1 and R2 are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

  本发明涉及一般式（I）的氨基取代异噻唑化合物，其中A、R1和R2如权利要求中定义的，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和配方，以及利用所述化合物制造用于治疗或预防疾病，特别是肿瘤的药物组合物的用途，作为单一药剂或与其他活性成分联合使用。
• HETEROCYCLYL COMPOUNDS AS MEK INHIBITORS
  申请人：LUPIN LIMITED

  公开号：US20150133424A1

  公开（公告）日：2015-05-14

  The present disclosure is related to heteroaryl compounds as MEK inhibitors. These compounds include heteroaryl compounds of formula I, their pharmaceutically acceptable salts, combinations with suitable medicament and pharmaceutical compositions thereof. The present disclosure also includes processes of preparation of the compounds and their use in methods of treatment. The compounds as disclosed herein are of Formula (I) below:

  本公开涉及杂环芳基化合物作为MEK抑制剂。这些化合物包括式I的杂环芳基化合物，它们的药用盐，与合适药物的组合以及其制剂。本公开还包括所述化合物的制备方法和它们在治疗方法中的应用。所述化合物的化学式如下：